Neoleukin Therapeutics : Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome - Form 8-K -December 19, 2023 at 07:34 am EST
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome Two pediatric patients with Rett...
Source: marketscreener.com